Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs Pharmaceutical TechnologyFour cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.OncologyRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaceutical Technology Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications. Oncology Read full story Post navigation Previous: ECO 2026: gut hormone signals differ in T1D with obesityNext: FDA hands BeOne, Taiho approvals for blood cancers Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026